By integrating blood proteomics and metabolomics, we can gain novel insights into the immune and metabolic processes specific to ACPA– and ACPA+ RA, as well as the coordinated mechanisms (e.g., enzymes and their substrates or products) through which proteins and metabolites influence disease onset and progression (22). This evidence concerns the gene PRTN3 and rheumatoid arthritis.